Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Toremifene Versus Tamoxifen in Advanced Breast Cancer
2026-08-27
This Cochrane review synthesized randomized evidence comparing two estrogen receptor-directed endocrine therapies in advanced breast cancer. It found no clear efficacy advantage for toremifene or tamoxifen across tumor response, disease control, progression, or survival, while highlighting the importance of separating clinical comparability from molecular or tissue-level equivalence.
-
MK-4827 (Niraparib) in DNA Repair Research
2026-08-26
MK-4827 (Niraparib) provides a controlled way to model PARP-1/-2 inhibition, synthetic lethality, and DNA damage response failure in cancer cells. This workflow-focused guide connects BRCA-mutant assays with cisplatin-sequential treatment, radiosensitization, and practical resistance studies.
-
EdU Flow Cytometry Assay Kits (Cy5) Workflow
2026-08-26
Turn a short EdU pulse into a quantitative view of S-phase entry, proliferation, and treatment response without harsh DNA denaturation. This workflow shows how K1078 supports multiplexed cell-cycle studies, cancer research cell proliferation experiments, genotoxicity testing, and pharmacodynamic decision-making.
-
AZD0156 Workflow for ATM Kinase Inhibition
2026-08-25
AZD0156 enables selective ATM pathway interrogation across DNA damage, checkpoint, and combination-response assays. This workflow emphasizes exposure control, orthogonal readouts, and troubleshooting so researchers can distinguish genuine ATM dependence from nonspecific cytotoxicity.
-
Dacomitinib (PF-00299804) Lab Workflows
2026-08-25
A scenario-based guide to using Dacomitinib (PF-00299804), SKU A8319, in reproducible viability, proliferation, and cytotoxicity workflows. It connects pan-HER signaling, apoptosis, assay compatibility, ferroptosis interpretation, and practical product selection without overstating evidence.
-
p-tau Ser356, Alzheimer’s Pathology, and NUAK Inhibition
2026-08-24
Taylor and colleagues show that p-tau Ser356 increases with Alzheimer’s disease Braak stage and is broadly present in neurofibrillary tangles, with nanoscale evidence of synaptic colocalization. Their ex vivo experiments further reveal that NUAK inhibition produces distinct tau responses in postnatal mouse and adult human brain slice cultures, an important consideration for translational therapeutic studies.
-
Hydroxychloroquine Sulfate Workflow Guide
2026-08-24
Hydroxychloroquine Sulfate (SKU B4874) provides an aqueous-compatible way to investigate autophagy pathway modulation and TLR7/9-dependent immune activation in autoimmune disease research. It is suited to freshly prepared, water-based workflows, but should not be selected for protocols requiring DMSO or ethanol solubility or prolonged storage of solutions.
-
7-Ethyl-10-hydroxycamptothecin Workflow Guide
2026-08-23
Build reproducible SN-38 experiments around topoisomerase I poisoning, apoptosis, and S-phase/G2 profiling in metastatic colon cancer models. Extend conventional cytotoxicity assays with the FUBP1–FUSE interaction assay to distinguish canonical DNA damage from transcriptional regulatory effects.
-
Omeprazole A2845: Acid Secretion Workflow
2026-08-22
Omeprazole (SKU A2845) is a research-grade H+,K+-ATPase inhibitor for controlled gastric acid secretion experiments, antiulcer activity studies, and related assay development. This guide covers dossier-based handling and QC while defining boundaries: it is not intended for diagnostic, clinical, or medical use.
-
SIS3: A Mechanistic Probe of TGF-β/SMAD3
2026-08-22
SIS3, a selective Smad3 inhibitor, offers a rigorous way to test TGF-β/SMAD3 dependency in cancer and fibrosis research. This article connects SIS3 pharmacology with super-enhancer-driven lung adenocarcinoma biology and translates that insight into practical assay decisions.
-
BRD4770: G9a Histone Methyltransferase Inhibitor
2026-08-21
BRD4770 is a research-focused G9a histone methyltransferase inhibitor for connecting H3K9 methylation changes with senescence and cancer-cell growth phenotypes. This workflow-oriented guide covers formulation challenges, PANC-1 assays, mechanistic controls, and how to interpret findings alongside BRD4–RAC1 pathway research.
-
Polybrene: From Transduction Aid to Translational Tool
2026-08-20
Polybrene (Hexadimethrine Bromide) is more than a viral delivery additive: it is a controllable experimental variable that can influence attachment, uptake, transfection performance, and assay interpretation. This thought-leadership perspective connects its delivery mechanism with recent findings on mitochondrial proteostasis and outlines a disciplined path from improved transduction to translationally credible conclusions.
-
DCPS Links m7G Regulation to Diabetic Foot Ulcer Repair
2026-08-20
Xiao et al. identify the decapping scavenger enzyme DCPS as an m7G-related biomarker associated with diabetic foot ulcer pathology and epithelial repair. Integrating transcriptomic analysis with keratinocyte experiments, the study links reduced DCPS to impaired cell-cycle progression, proliferation, migration, and increased apoptosis, while also highlighting limitations that should be addressed before clinical translation.
-
Jiao-tai-wan, Coptisine, and SIRT1 in PCOS
2026-08-19
A 2025 Phytomedicine study identifies mitochondrial cholesterol import as a mechanistic link between SIRT1 regulation and abnormal ovarian steroidogenesis in a DHEA-induced PCOS model. Its evidence suggests that Jiao-tai-wan and coptisine act partly by limiting SMURF2-mediated SIRT1 degradation, thereby altering StAR localization and theca-cell steroidogenic activity.
-
Pol II Degradation and Transcription-Independent Cell Death
2026-08-19
The preprint argues that degradation of RNA polymerase II (Pol II) can activate cell death through a mechanism that is not simply a consequence of transcriptional collapse. Its main contribution is conceptual and experimental: it separates the effects of losing Pol II protein from the effects of losing transcription, providing a framework for interpreting regulated cell-death phenotypes after transcriptional perturbation.